Qualitek LabsBOM:544091 -1.66%46 EBITDA Margin % is 26.33% as of Mar. 2026, which is 10% above its 10-year median of 23.91. GuruFocus rates BOM:544091 with a GF Score™ of 46/100. The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Qualitek Labs ranks better than 79.8% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Qualitek Labs's EBITDA for the
six
months ended in Mar. 2026 was ₹185 Mil. Qualitek Labs's Revenue for the
six
months ended in Mar. 2026 was ₹703 Mil. Therefore, Qualitek Labs's EBITDA margin for the quarter that ended in Mar. 2026 was 26.33%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Qualitek Labs EBITDA Margin % Related Terms
Qualitek Labs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Qualitek Labs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544091 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Qualitek Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qualitek Labs EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qualitek Labs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Qualitek Labs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qualitek Labs (BOM:544091) has a EBITDA Margin % of 26.33% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qualitek Labs and its competitors. This is 10% above median its historical median of 23.91. Over the past decade, Qualitek Labs' EBITDA Margin % has ranged from 10.64 to 28.62. According to the industry distribution chart, Qualitek Labs ranks #41 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 20.2%.
Is Qualitek Labs' EBITDA Margin % too high?
Qualitek Labs' current EBITDA Margin % of 26.33% is 10% above median its 10-year median of 23.91. Over the past 10 years, this metric has ranged from a low of 10.64 to a high of 28.62. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Qualitek Labs' value of 26.33% is 426.6% above this industry median. Based on the distribution chart, Qualitek Labs ranks #41 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Qualitek Labs has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Qualitek Labs' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Qualitek Labs ranks #41 out of 203 companies for EBITDA Margin %. This places Qualitek Labs in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Qualitek Labs' value of 26.33% is 426.6% above this benchmark. Historically, Qualitek Labs' own EBITDA Margin % has ranged from 10.64 to 28.62 over the past decade. While the company's 10-year median is 23.91 vs. the industry median of 5.00, Qualitek Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qualitek Labs's current EBITDA Margin % of 26.33% is 426.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Qualitek Labs and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qualitek Labs's current EBITDA Margin % is 26.33%, which is 10% above median its own 10-year median of 23.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qualitek Labs stock overvalued right now?
Qualitek Labs (BOM:544091) has a current EBITDA Margin % of 26.33%. The current EBITDA Margin % is 26.33%, which is 10% above median its 10-year median of 23.91 and 426.6% above the Medical Diagnostics & Research industry median of 5.00. Qualitek Labs' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Qualitek Labs (BOM:544091), the current EBITDA Margin % is 26.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qualitek Labs Ltd is engaged in the business of providing testing, inspection, homologation, certification, and consultancy services to various industries such as automotive, defence, metals & metallurgy, environment and water, minerals, food & agriculture, pharma & healthcare.
46GF Score
Get the complete analysis for BOM:544091
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544091 has been successfully added to your 
